Alzheimer's disease (AD) involves Aβ and tau pathology, initiating years before symptoms. the apolipoprotein E ε4 allele (APOE ε4) is the major genetic risk factor, influencing neurodegeneration and functional network disruption. This study investigates how APOE ε4 modulates the default mode network (DMN)'s hierarchical organization to accelerate cognitive decline.
Objective
This study aimed to elucidate how APOE ε4 accelerates AD pathological progression by altering the functional gradient hierarchy of DMN, and to evaluate the potential of DMN gradient abnormalities as an early diagnostic biomarker for AD.
Methods
We enrolled 271 participants, categorized by diagnosis and APOE ε4 status. All underwent neuropsychological assessment, plasma Aβ42/40 measurement, and resting-state functional MRI. DMN functional gradients were quantified using the BrainSpace toolbox. Statistical analyses included a 2 × 2 factorial design, mediation analysis, and correlation testing with cognitive scores.
Results
A significant Group × Genotype interaction was identified in the right inferior temporal gyrus (RITG). AD patients with APOE ε4 showed the most severe gradient attenuation, while non-carrier patients exhibited compensatory elevation. The RITG gradient correlated with multiple cognitive domains exclusively in APOE ε4 carriers. Altered connectivity between the left superior frontal gyrus (LSFG) and RITG mediated the effect of Aβ burden on gradient disruption.
Conclusions
APOE ε4 accelerates cognitive decline in AD by specifically disrupting the DMN functional gradient hierarchy, particularly within the right ITG. Amyloid-β deposition contributes to macro-scale DMN topological disorganization by impairing LSFG-RITG functional connectivity. DMN functional gradient mapping provides a sensitive biomarker for early AD diagnosis and a novel target for APOE ε4-targeted interventions.
HardyJAHigginsGA. Alzheimer’s disease: the amyloid cascade hypothesis. Science1992; 256: 184–185.
2.
ScheltensPDe StrooperBKivipeltoM, et al.Alzheimer’s disease. Lancet2021; 397: 1577–1590.
3.
HanssonO. Biomarkers for neurodegenerative diseases. Nat Med2021; 27: 954–963.
4.
TerryRDMasliahESalmonDP, et al.Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol1991; 30: 572–580.
5.
IttnerLMGötzJ. Amyloid-β and tau–a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci2011; 12: 65–72.
6.
JackCRKnopmanDSJagustWJ, et al.Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol2010; 9: 119–128.
7.
MorrisJCRoeCMXiongC, et al.APOE Predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol2010; 67: 122–131.
8.
CorderEHSaundersAMStrittmatterWJ, et al.Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science1993; 261: 921–923.
9.
FarrerLACupplesLAHainesJL, et al.Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA1997; 278: 1349–1356.
10.
LambertJ-CIbrahim-VerbaasCAHaroldD, et al.Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet2013; 45: 1452–1458.
11.
RebeckGWReiterJSStricklandDK, et al.Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions. Neuron1993; 11: 575–580.
LiuC-CZhaoNFuY, et al.Apoe4 accelerates early seeding of amyloid pathology. Neuron2017; 96: 1024–1032.e3.
14.
ZhaoNRenYYamazakiY, et al.Alzheimer’s risk factors age, APOE genotype, and sex drive distinct molecular pathways. Neuron2020; 106: 727–742.e6.
15.
LinY-TSeoJGaoF, et al.APOE4 Causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types. Neuron2018; 98: 1141–1154.e7.
16.
ZhaoJDavisMDMartensYA, et al.APOE Ε4/ε4 diminishes neurotrophic function of human iPSC-derived astrocytes. Hum Mol Genet2017; 26: 2690–2700.
17.
ChungW-SVerghesePBChakrabortyC, et al.Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Proc Natl Acad Sci U S A2016; 113: 10186–10191.
18.
LyMYuGZMianA, et al.Neuroinflammation: a modifiable pathway linking obesity, Alzheimer’s disease, and depression. Am J Geriatr Psychiatry2023; 31: 853–866.
19.
ShiYYamadaKLiddelowSA, et al.Apoe4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature2017; 549: 523–527.
20.
ShiYManisMLongJ, et al.Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J Exp Med2019; 216: 2546–2561.
21.
MishraSBlazeyTMHoltzmanDM, et al.Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype. Brain2018; 141: 1828–1839.
22.
LiBShiJGutmanBA, et al.Influence of APOE genotype on hippocampal atrophy over time - an N=1925 surface-based ADNI study. PLoS One2016; 11: e0152901.
23.
SmithCDAndersenAHKryscioRJ, et al.Altered brain activation in cognitively intact individuals at high risk for Alzheimer’s disease. Neurology1999; 53: 1391–1396.
24.
FilippiniNMacIntoshBJHoughMG, et al.Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci U S A2009; 106: 7209–7214.
25.
JonesDTKnopmanDSGunterJL, et al.Cascading network failure across the Alzheimer’s disease spectrum. Brain2016; 139: 547–562.
26.
DamoiseauxJSPraterKEMillerBL, et al.Functional connectivity tracks clinical deterioration in Alzheimer’s disease. Neurobiol Aging2012; 33: 828.e19–30.
27.
ShelineYIMorrisJCSnyderAZ, et al.APOE4 Allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. J Neurosci2010; 30: 17035–17040.
28.
HuntenburgJMBazinP-LMarguliesDS. Large-scale gradients in human cortical organization. Trends Cogn Sci2018; 22: 21–31.
29.
LiuXChenXChengJ, et al.Functional connectivity gradients and neurotransmitter maps among patients with mild cognitive impairment and depression symptoms. J Psychiatry Neurosci2025; 50: E11–E20.
30.
HongS-JXuTNikolaidisA, et al.Toward a connectivity gradient-based framework for reproducible biomarker discovery. Neuroimage2020; 223: 117322.
31.
YangDLiJKeZ, et al.Subsystem mechanisms of default mode network underlying white matter hyperintensity-related cognitive impairment. Hum Brain Mapp2023; 44: 2365–2379.
32.
Vos de WaelRBenkarimOPaquolaC, et al.Brainspace: a toolbox for the analysis of macroscale gradients in neuroimaging and connectomics datasets. Commun Biol2020; 3: 103.
33.
SchaeferAKongRGordonEM, et al.Local-global parcellation of the human cerebral cortex from intrinsic functional connectivity MRI. Cereb Cortex2018; 28: 3095–3114.
YanC-GWangX-DZuoX-N, et al.DPABI: data processing & analysis for (resting-state) brain imaging. Neuroinformatics2016; 14: 339–351.
36.
Tzourio-MazoyerNLandeauBPapathanassiouD, et al.Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage2002; 15: 273–289.
37.
JonesDTMachuldaMMVemuriP, et al.Age-related changes in the default mode network are more advanced in Alzheimer disease. Neurology2011; 77: 1524–1531.
38.
LinY-HYoungIMConnerAK, et al.Anatomy and white matter connections of the inferior temporal gyrus. World Neurosurg2020; 143: e656–e666.
39.
WuY-QWangY-NZhangL-J, et al.Regional homogeneity in patients with mild cognitive impairment: a resting-state functional magnetic resonance imaging study. Front Aging Neurosci2022; 14: 877281.
40.
ConvitAde AsisJde LeonMJ, et al.Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer’s disease. Neurobiol Aging2000; 21: 19–26.
41.
FranzmeierNNeitzelJRubinskiA, et al.Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease. Nat Commun2020; 11: 347.
42.
WangYLiQYaoL, et al.Shared and differing functional connectivity abnormalities of the default mode network in mild cognitive impairment and Alzheimer’s disease. Cereb Cortex2024; 34: bhae094.
43.
RaichleMEMacLeodAMSnyderAZ, et al.A default mode of brain function. Proc Natl Acad Sci U S A2001; 98: 676–682.
44.
JanelidzeSTeunissenCEZetterbergH, et al.Head-to-head comparison of 8 plasma amyloid-β 42/40 assays in Alzheimer disease. JAMA Neurol2021; 78: 1375–1382.
45.
DarkHEShaferATCordonJ, et al.Association of plasma biomarkers of Alzheimer disease and neurodegeneration with longitudinal intra-network functional brain connectivity. Neurology2025; 104: e210271.
46.
KoutsodendrisNNelsonMRRaoA, et al.Apolipoprotein E and Alzheimer’s disease: findings, hypotheses, and potential mechanisms. Annu Rev Pathol2022; 17: 73–99.
